Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Carbapenem

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioVersys Presents Clinical and Preclinical Data at Global ESCMI
    BioVersys Presents Clinical and Preclinical Data at Global ESCMI

    15 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/15/3274109/0/en/BioVersys-to-Present-Data-on-Clinical-and-Preclinical-Pipeline-Programs-at-ESCMID-Global-2026.html

    GLOBENEWSWIRE
    15 Apr 2026
    Share Share
    FDA Clears BioVersys BV100 for Phase 3 HABP/VABP Trials
    FDA Clears BioVersys BV100 for Phase 3 HABP/VABP Trials

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3255983/0/en/BioVersys-Receives-Green-Light-from-US-FDA-for-BV100-HABP-VABP-Phase-3-Pivotal-Trial-Start.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    DoP Re-opens Online Submission For PLI Scheme For 2 Bulk Drugs
    DoP Re-opens Online Submission For PLI Scheme For 2 Bulk Drugs

    23 Feb 2026

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=184391&sid=1

    PHARMABIZ
    23 Feb 2026
    Share Share
    DoP Extends PLI Timeline for Bulk Drugs to Jan. 16, 2026
    DoP Extends PLI Timeline for Bulk Drugs to Jan. 16, 2026

    30 Dec 2025

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=183296&sid=1

    PHARMABIZ
    30 Dec 2025
    Share Share
    GSK Resubmits Tebipenem HBr NDA To FDA For Complicated UTIs
    GSK Resubmits Tebipenem HBr NDA To FDA For Complicated UTIs

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208446/0/en/Spero-Announces-NDA-Resubmission-of-Tebipenem-HBr-by-GSK-to-the-FDA-for-the-Treatment-of-Complicated-Urinary-Tract-Infections-Including-Pyelonephritis.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    DoP Seeks Applications For PLI Scheme To Produce 2 Bulk Drugs
    DoP Seeks Applications For PLI Scheme To Produce 2 Bulk Drugs

    01 Dec 2025

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=182742&sid=1

    PHARMABIZ
    01 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.